BC
BCYC.US Bicycle Therapeutics Ltd
- Market cap
- USD 236M
- P/E
- -
- P/B
- 0.48x
- ROE
- -32.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BCYC.US undervalued?
Graham numberThe Graham number of Bicycle Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bicycle Therapeutics Ltd fundamental analysis
No fundamental analysis for Bicycle Therapeutics Ltd yet.
Bicycle Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin t…
Full company profileBicycle Therapeutics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bicycle Therapeutics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 2.06M | 7.14M | 13.8M | 10.4M | 11.7M | 14.5M | 27.0M | 35.3M | 72.6M | 47.4M |
| Gross Profit | -269K | -9.81M | -13.6M | 13.8M | -22.8M | 11.7M | 14.5M | -130M | -138M | 72.6M | 47.4M |
| Operating Income | -13.5M | -16.2M | -21.7M | -26.3M | -52.0M | -65.6M | -117M | -190M | -210M | -248M | -178M |
| EBITDA | -13.3M | -15.9M | -21.5M | -25.3M | -50.7M | -64.1M | -107M | -169M | -165M | -212M | -156M |
| Net Income | -13.5M | -16.3M | -21.8M | -30.6M | -51.0M | -66.8M | -113M | -181M | -169M | -219M | -162M |
| EPS | -0.76 | -1.22 | -1.64 | -2.77 | -2.66 | -2.67 | -3.80 | -5.08 | -2.90 | -3.16 | -2.32 |
| Balance Sheet | |||||||||||
| Total Assets | 11.8M | 74.0M | 81.6M | 110M | 161M | 480M | 411M | 595M | 957M | 718M | 567M |
| Total Liabilities | 3.81M | 121M | 151M | 17.0M | 65.7M | 134M | 140M | 224M | 164M | 108M | 61.9M |
| Shareholders' Equity | 8.02M | -47.2M | -69.8M | 93.2M | 95.5M | 346M | 271M | 371M | 793M | 610M | 505M |
| Cash & Short-term Investments | 9.40M | 67.7M | 63.4M | 92.1M | 136M | 439M | 339M | 526M | 880M | 628M | 470M |
| Total Debt | - | - | - | 1.89M | 15.8M | 44.3M | 44.3M | 45.0M | 9.49M | 17.5M | 14.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.3M | -1.42M | -26.1M | -28.6M | -17.8M | -14.8M | -86.1M | -60.6M | -165M | -250M | -208M |
| Capital Expenditure | 243K | 1.11M | 1.19M | 1.56M | 1.20M | 2.03M | 19.0M | 2.93M | 1.24M | 2.36M | 1.71M |
| Free Cash Flow | -11.5M | -2.53M | -27.3M | -30.2M | -19.0M | -16.8M | -105M | -63.6M | -166M | -252M | -209M |
| Ratios | |||||||||||
| ROE | -168.4% | - | - | -32.8% | -53.4% | -19.3% | -41.6% | -48.7% | -21.3% | -35.9% | -32.1% |
| ROA | -114.2% | -22.0% | -26.8% | -27.8% | -31.7% | -13.9% | -27.5% | -30.3% | -17.7% | -30.5% | -28.6% |
| Net Profit Margin | - | -789.3% | -306.1% | -221.8% | -491.0% | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% | -341.9% |
| Debt to Equity | - | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bicycle Therapeutics Ltd dividends
Bicycle Therapeutics Ltd has not paid dividends in the last 9 fiscal years.
Who owns Bicycle Therapeutics Ltd
- Insiders 4.58%
- Institutions 70.98%
- Public & others 24.44%
- Shares outstanding 50.7M
- Free float 7.76M
Top funds holding BCYC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| International Biotechnology Ord | 616K | 0.88% | 0.00% | Jul 2026 |
| iShares Biotechnology ETF | 291K | 0.42% | -0.19% | Oct 2026 |
| Old Westbury Small & Mid Cap Strategies | 266K | 0.38% | 0.00% | Jul 2026 |
| Virtus Biotech Clinical Trials ETF | 66.0K | 0.09% | 0.00% | Oct 2026 |
| ALPS Medical Breakthroughs ETF | 61.4K | 0.09% | 0.00% | Oct 2026 |
| PPF Helix Biotechnology I USD | 58.3K | 0.08% | 0.00% | Jul 2026 |
| TD Health Sciences - I | 46.0K | 0.07% | 0.00% | Jun 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 39.7K | 0.06% | +0.21% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 37.4K | 0.05% | 0.00% | Oct 2026 |
| Voya Multi-Manager International Sm Cp A | 30.1K | 0.04% | 0.00% | Jun 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 28.5K | 0.04% | +1.92% | Oct 2026 |
| Acadian Eurp Eq C2-i-0.7500-EUR | 26.0K | 0.04% | 0.00% | Jun 2026 |
| JHVIT Health Sciences I | 25.6K | 0.04% | 0.00% | Aug 2026 |
| Acadian European SmCp Eq C2-i-0.7500-EUR | 24.1K | 0.03% | 0.00% | Jun 2026 |
| ActivePassive International Equity ETF | 20.4K | 0.03% | 0.00% | Oct 2026 |
| Portland Life Sciences Alt F | 15.0K | 0.02% | 0.00% | Sep 2026 |
| ERSTE STOCK BIOTEC EUR R01 A | 14.0K | 0.02% | 0.00% | Aug 2026 |
| The AtonRâ Fund Founder USD Acc | 11.6K | 0.02% | -21.15% | Jun 2026 |
| Horizon Kinetics Medical ETF | 11.4K | 0.02% | 0.00% | Oct 2026 |
| Steward Values Enhanced International I | 11.2K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding BCYC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 10.9M | 15.55% | 0.00% | Jun 2026 |
| FCPM III SERVICES BV | 3.47M | 4.96% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 3.40M | 4.85% | 0.00% | Jun 2026 |
| Long Focus Capital Management, LLC | 3.31M | 4.73% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 1.97M | 2.81% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.53M | 2.19% | +56.58% | Jun 2026 |
| GSK PLC | 1.53M | 2.19% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 902K | 1.29% | -12.26% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 798K | 1.14% | +111.47% | Jun 2026 |
| Qube Research & Technologies | 776K | 1.11% | +151.30% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 667K | 0.95% | +7.92% | Jun 2026 |
| Schroder Investment Management Group | 616K | 0.88% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 554K | 0.79% | +46.98% | Jun 2026 |
| Millennium Management LLC | 554K | 0.79% | +95.07% | Jun 2026 |
| Peapod Lane Capital LLC | 538K | 0.77% | +344.22% | Jun 2026 |
| Diadema Partners LP | 463K | 0.66% | -2.88% | Jun 2026 |
| Two Sigma Investments LLC | 435K | 0.62% | +163.70% | Jun 2026 |
| Jane Street Group LLC | 392K | 0.56% | +79.80% | Jun 2026 |
| FLAX POND CAPITAL, LLC | 376K | 0.54% | +113.60% | Jun 2026 |
| Birchview Capital, LP | 314K | 0.45% | -32.35% | Jun 2026 |
Bicycle Therapeutics Ltd company profile
- Company name
- Bicycle Therapeutics Ltd
- Ticker
- BCYC.US
- Exchange
- USA Stocks
- Listed since
- May 23, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 288
- Fiscal year end
- December
- Address
- Portway Building, Cambridge, United Kingdom, CB21 6GS
- Phone
- 44 1223 261 503
- Website
- bicycletherapeutics.com
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics Ltd management
10- Dr. Kevin Lee M.B.A., Ph.D.CEO & Executive Director · born 1968
- Dr. Michael Skynner B.sc. Ph.d., Ph.D.Chief Scientific Officer · born 1969
- Mr. Alistair MilnesChief Corporate Development Officer · born 1974
- Dr. Christian HeinisScientific Founder
- Mr. Travis ThompsonChief Financial Officer · born 1980
- Dr. Jennifer Perry Pharm.D.Chief Operating Officer · born 1974
- Ms. Stephanie YaoSenior Vice President of Investor Relations and Corporate Communications
- Mr. Zafar QadirChief Legal Officer & General Counsel
- Dr. Phil JeffreySenior VP of Pre-Clinical Development
- Dr. Michael Charles-Ferguson HannayChief Product & Supply Chain Officer · born 1966